Matthew Turner

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

Pere Gascón, Matti Aapro, Heinz Ludwig et al. · Supportive Care in Cancer · 2015 · 66 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study

Heinz Ludwig, Matti Aapro, Carsten Bokemeyer et al. · European Journal of Cancer · 2009 · 66 citations

Medicine, Hematology, Oncology +14

Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study

José Luis Fernández Martín, Adriana Dusso, Pablo Martínez‐Camblor et al. · Nephrology Dialysis Transplantation · 2018 · 32 citations

Medicine, Endocrinology, Nephrology +17

Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective

Hillel P. Cohen, Matthew Turner, Dorothy McCabe et al. · BioDrugs · 2023 · 26 citations · Full text

Pharmacy, Pharmacology, Bioequivalence +16

Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim

Pere Gascón, Matti Aapro, Heinz Ludwig et al. · Critical Reviews in Oncology/Hematology · 2010 · 24 citations

Medicine, Pharmacology, Pharmacotherapy +14